

**PRIOR AUTHORIZATION REQUEST FORM**
**CHRONIC OPIOID MEDICATIONS**

## Chronic Opioid Medications

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

*Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.*

Product being requested: \_\_\_\_\_

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section**

Questions	Yes	No	Comments/Notes
<b>NON-CANCER, CHRONIC PAIN TOTAL MME &lt; 60</b>			
1. Does the member have a diagnosis of active cancer? If yes, no further assessment is required.	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Has the member signed a pain contract or informed consent and treatment agreement for chronic opioid therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Does documentation show that the prescriber has monitored the member's urine drug screen results within the last 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>NON-CANCER, CHRONIC PAIN TOTAL MME ≥ 60</b>			
1. Does the member have a diagnosis of active cancer? If yes, no further assessment is required.	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Will the requested therapy exceed 200 morphine milligram equivalents (MME) per day? <b>If yes, an active taper plan is required for authorization.</b>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide taper plan</b>
3. Does documentation show that non-pharmacologic treatments such as physical therapy, cognitive behavioral therapy, etc. have been tried but are inadequate?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

4. Does documentation show a trial and failure of non-opioid medications (e.g., acetaminophen, NSAIDs, antidepressants, muscle relaxants, topical analgesics, etc.)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation, including names, dates, and durations of treatments</b>
5. Does the member's pain impact their ability to perform activities of daily living and/or is causing significant psychological issues?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. Is there a treatment plan in place that outlines the goals of therapy and how the member's progress will be evaluated (e.g., pain levels, functional status, etc. from baseline)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
7. Has the member signed a pain contract or informed consent and treatment agreement for chronic opioid therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
8. Does documentation show that the prescriber has monitored the member's urine drug screen results within the last 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
9. Has the member been offered a prescription and training for nasally administered naloxone?	<input type="checkbox"/>	<input type="checkbox"/>	
10. Is the requested therapy for opioid addiction treatment?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
11. Is the member being treated with duplicate short-acting opioids? <b>Documentation showing that a single short-acting agent is not sufficient or appropriate, is required.</b>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
12. Is the member also being treated with a benzodiazepine (e.g., lorazepam, alprazolam, etc.)? <b>Documentation showing medical necessity is required.</b>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
13. Is the member also being treated with carisoprodol (Soma)? <b>Opioid treatment in combination with carisoprodol will not be covered.</b>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
14. Is the prescriber reviewing the member's history of controlled substance prescriptions using the states prescription drug monitoring program at least every 3 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>LONG ACTING OPIOIDS</b>			
1. Is the request for a long-acting opioid?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member require daily, around-the-clock long-term opioid treatment?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member tried and failed short-acting opioids along with non-pharmacological therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Is the member currently on opioid therapy that is at least 20 MMEs per day?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Does the member have a past or current substance abuse potential? <b>Documentation showing medical necessity for opioid treatment is required.</b>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member shown objective progress toward treatment plan goals?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member continued to utilize physical, behavioral, and non-opioid therapies in combination with chronic opioid therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

4. Has a random drug screen been performed within the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Do the member's medication records correspond with medical reasons for continuing or modifying opioid therapy (i.e., medication, dose, and quantities prescribed)?	<input type="checkbox"/>	<input type="checkbox"/>	
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy PHARM-051  
 Origination Date: 08/21/2017  
 Reviewed/Revised Date: 03/15/2023  
 Next Review Date: 03/15/2024  
 Current Effective Date: 04/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.